Genovis (GENO.ST) Stock Price

Genovis Price

OMX·CLOSED
19.78SEK+0.44 (+2.25 %)
Market closed

Revenue has compounded at 41.2% per year over the past 18 years to 128.95 M SEK. Earnings per share have grown at 15.3% per year over the last 6 years. Genovis's net margin stands at 18.2%, down from 26.6% several years earlier. Analysts set a median price target of 30.60 SEK, implying 54.7% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 22% above its 52-week low.

Genovis stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Genovis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Genovis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Genovis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Genovis Stock Price History
DateGenovis Price
8/6/202619.78 SEK
8/5/202619.34 SEK
8/4/202619.12 SEK
7/31/202619.58 SEK
7/30/202619.90 SEK
7/29/202619.60 SEK
7/28/202619.50 SEK
7/27/202620.05 SEK
7/24/202620.05 SEK
7/23/202618.64 SEK
7/22/202619.46 SEK
7/21/202619.28 SEK
7/20/202619.24 SEK
7/17/202619.20 SEK
7/16/202618.92 SEK
7/15/202619.12 SEK
7/14/202619.38 SEK
7/13/202619.22 SEK
7/10/202618.98 SEK
7/9/202619.00 SEK
7/8/202618.86 SEK
7/7/202619.20 SEK
7/6/202619.36 SEK
7/3/202620.40 SEK
7/2/202620.80 SEK
7/1/202620.50 SEK
6/30/202619.70 SEK
6/29/202619.36 SEK
6/26/202619.46 SEK
6/25/202619.36 SEK
6/24/202618.90 SEK
6/23/202618.52 SEK
6/22/202618.56 SEK
6/18/202618.32 SEK
6/17/202618.50 SEK
6/16/202619.00 SEK
6/15/202619.50 SEK
6/12/202619.58 SEK
6/11/202619.94 SEK
6/10/202619.50 SEK
6/9/202619.20 SEK
6/8/202619.40 SEK
6/5/202619.70 SEK
6/4/202619.86 SEK
6/3/202619.34 SEK
6/2/202620.10 SEK
6/1/202620.10 SEK
5/29/202620.20 SEK
5/28/202620.10 SEK
5/27/202619.56 SEK
5/26/202619.22 SEK
5/25/202620.55 SEK
5/22/202620.45 SEK
5/21/202620.25 SEK
5/20/202620.05 SEK
5/19/202620.60 SEK
5/18/202620.00 SEK
5/15/202620.65 SEK
5/13/202621.00 SEK
5/12/202619.64 SEK
5/11/202620.90 SEK
5/8/202620.15 SEK
5/7/202620.60 SEK
5/6/202619.98 SEK
5/5/202619.80 SEK
5/4/202619.90 SEK
4/30/202619.40 SEK
4/29/202618.92 SEK
4/28/202619.36 SEK
4/27/202620.05 SEK
4/24/202619.94 SEK
4/23/202620.30 SEK
4/22/202620.30 SEK
4/21/202620.15 SEK
4/20/202619.96 SEK
4/17/202620.10 SEK
4/16/202620.20 SEK
4/15/202620.50 SEK
4/14/202620.20 SEK
4/13/202619.84 SEK
4/10/202619.80 SEK
4/9/202618.94 SEK
4/8/202619.48 SEK
4/7/202619.06 SEK
4/2/202619.44 SEK
4/1/202618.52 SEK
3/31/202618.06 SEK
3/30/202616.76 SEK
3/27/202617.10 SEK
3/26/202618.00 SEK
3/25/202618.40 SEK
3/24/202616.16 SEK
3/23/202616.46 SEK
3/20/202616.20 SEK
3/19/202616.38 SEK
3/18/202616.16 SEK
3/17/202616.20 SEK
3/16/202616.66 SEK
3/13/202616.72 SEK
3/12/202616.54 SEK
3/11/202616.68 SEK
3/10/202616.68 SEK
3/9/202616.60 SEK
3/6/202616.68 SEK
3/5/202616.74 SEK
3/4/202617.00 SEK
3/3/202616.72 SEK
3/2/202616.90 SEK
2/27/202617.30 SEK
2/26/202617.20 SEK
2/25/202616.92 SEK
2/24/202617.30 SEK
2/23/202617.16 SEK
2/20/202616.96 SEK
2/19/202617.06 SEK
2/18/202617.02 SEK
2/17/202616.98 SEK
2/16/202617.50 SEK
2/13/202617.70 SEK
2/12/202617.90 SEK
2/11/202619.72 SEK
2/10/202619.62 SEK
2/9/202620.45 SEK
2/6/202620.45 SEK
2/5/202620.00 SEK
2/4/202620.45 SEK
2/3/202620.40 SEK
2/2/202621.10 SEK
1/30/202621.65 SEK
1/29/202622.00 SEK
1/28/202622.55 SEK
1/27/202623.00 SEK
1/26/202622.90 SEK
1/23/202622.15 SEK
1/22/202621.80 SEK
1/21/202620.65 SEK
1/20/202620.75 SEK
1/19/202621.10 SEK
1/16/202621.70 SEK
1/15/202621.40 SEK
1/14/202621.60 SEK
1/13/202621.65 SEK
1/12/202621.60 SEK
1/9/202621.80 SEK
1/8/202621.50 SEK
1/7/202621.45 SEK
1/5/202620.85 SEK
1/2/202621.75 SEK
12/30/202521.25 SEK
12/29/202521.25 SEK
12/23/202521.20 SEK
12/22/202520.75 SEK
12/19/202520.50 SEK
12/18/202520.00 SEK
12/17/202519.96 SEK
12/16/202519.38 SEK
12/15/202520.00 SEK
12/12/202520.50 SEK
12/11/202520.15 SEK
12/10/202519.80 SEK
12/9/202519.36 SEK
12/8/202519.86 SEK
12/5/202520.35 SEK
12/4/202520.45 SEK
12/3/202520.10 SEK
12/2/202519.94 SEK
12/1/202520.60 SEK
11/28/202520.20 SEK
11/27/202520.70 SEK
11/26/202520.75 SEK
11/25/202520.55 SEK
11/24/202519.92 SEK
11/21/202520.00 SEK
11/20/202520.05 SEK
11/19/202520.30 SEK
11/18/202520.00 SEK
11/17/202520.80 SEK
11/14/202520.70 SEK
11/13/202521.05 SEK
11/12/202521.10 SEK
11/11/202520.50 SEK
11/10/202520.65 SEK
11/7/202521.05 SEK
11/6/202522.05 SEK
11/5/202521.20 SEK
11/4/202522.55 SEK
11/3/202522.65 SEK
10/31/202523.05 SEK
10/30/202522.50 SEK
10/29/202522.75 SEK
10/28/202522.90 SEK
10/27/202523.20 SEK
10/24/202522.95 SEK
10/23/202523.00 SEK
10/22/202523.05 SEK
10/21/202523.20 SEK
10/20/202522.50 SEK
10/17/202522.70 SEK
10/16/202521.70 SEK
10/15/202521.25 SEK
10/14/202521.00 SEK
10/13/202520.60 SEK
10/10/202521.00 SEK
10/9/202522.70 SEK
10/8/202523.85 SEK
10/7/202523.85 SEK
10/6/202523.75 SEK
10/3/202523.95 SEK
10/2/202523.95 SEK
10/1/202523.80 SEK
9/30/202523.25 SEK
9/29/202523.20 SEK
9/26/202522.65 SEK
9/25/202523.00 SEK
9/24/202522.75 SEK
9/23/202523.90 SEK
9/22/202522.70 SEK
9/19/202523.00 SEK
9/18/202525.10 SEK
9/17/202524.60 SEK
9/16/202524.05 SEK
9/15/202523.50 SEK
9/12/202523.15 SEK
9/11/202523.35 SEK
9/10/202523.10 SEK
9/9/202523.20 SEK
9/8/202523.00 SEK
9/5/202523.00 SEK
9/4/202522.65 SEK
9/3/202522.80 SEK
9/2/202522.60 SEK
9/1/202523.60 SEK
8/29/202523.85 SEK
8/28/202524.25 SEK
8/27/202525.45 SEK
8/26/202525.35 SEK
8/25/202524.35 SEK
8/22/202524.00 SEK
8/21/202522.95 SEK
8/20/202523.65 SEK
8/19/202524.30 SEK
8/18/202523.70 SEK
8/15/202523.90 SEK
8/14/202525.20 SEK
8/13/202526.20 SEK
8/12/202527.10 SEK
8/11/202527.10 SEK
Access this data via the Eulerpool API
Get Free API Key

Genovis Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
158.23 M SEK
54.22 M SEK
61.50 M SEK
Jan 1, 2024
130.36 M SEK
45.73 M SEK
32.92 M SEK
Jan 1, 2025
128.95 M SEK
27.49 M SEK
23.50 M SEK
Jan 1, 2026 (e)
145.80 M SEK
36.57 M SEK
23.40 M SEK
Jan 1, 2027 (e)
183.18 M SEK
45.95 M SEK
37.97 M SEK
Jan 1, 2028 (e)
225.03 M SEK
56.45 M SEK
52.86 M SEK
Jan 1, 2029 (e)
265.00 M SEK
66.47 M SEK
65.47 M SEK
Jan 1, 2030 (e)
308.00 M SEK
77.26 M SEK
81.83 M SEK

Genovis Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 8:19 PM
 
REVENUEM SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
13.0018.0022.0034.0060.0061.0093.00102.00158.00130.00128.00145.00183.00225.00265.00308.00
62.5038.4622.2254.5576.471.6752.469.6854.90-17.72-1.5413.2826.2122.9517.7816.23
76.9294.4495.4597.0693.3393.4487.1085.2990.5187.6921.0921.0921.0921.0921.0921.09
10.0017.0021.0033.0056.0057.0081.0087.00143.00114.0027.0030.5938.6047.4655.9064.97
-19.00-14.00-7.00–13.006.0024.008.0054.0045.0027.0036.0045.0056.0066.0077.00
-146.15-77.78-31.82–21.679.8425.817.8434.1834.6221.0924.8324.5924.8924.9125.00
-19.00-15.00-7.00-1.009.006.0024.0011.0061.0032.0023.0023.0037.0052.0065.0081.00
-13.64-21.05-53.33-85.71-1,000.00-33.33300.00-54.17454.55-47.54-28.13–60.8740.5425.0024.62
38.9855.2960.2963.1063.1065.4765.4765.4765.4765.4766.0666.0666.0666.0666.0666.06
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Genovis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Genovis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Genovis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Genovis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Genovis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Genovis stock margins

The Genovis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genovis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genovis.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
87.39 %
26.39 %
26.64 %
Jan 1, 2022
85.33 %
8.36 %
10.93 %
Jan 1, 2023
90.42 %
34.27 %
38.87 %
Jan 1, 2024
88.20 %
35.08 %
25.25 %
Jan 1, 2025
21.32 %
21.32 %
18.22 %
Jan 1, 2026 (e)
21.32 %
25.08 %
16.05 %
Jan 1, 2027 (e)
21.32 %
25.08 %
20.73 %
Jan 1, 2028 (e)
21.32 %
25.08 %
23.49 %

Genovis Stock Revenue, EBIT, Earnings per Share

The Genovis earnings per share therefore indicates how much revenue Genovis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
1.42 SEK
0.37 SEK
0.38 SEK
Jan 1, 2022
1.56 SEK
0.13 SEK
0.17 SEK
Jan 1, 2023
2.42 SEK
0.83 SEK
0.94 SEK
Jan 1, 2024
1.99 SEK
0.70 SEK
0.50 SEK
Jan 1, 2025
1.95 SEK
0.42 SEK
0.36 SEK
Jan 1, 2026 (e)
2.23 SEK
0.55 SEK
0.36 SEK
Jan 1, 2027 (e)
2.80 SEK
0.70 SEK
0.58 SEK
Jan 1, 2028 (e)
3.44 SEK
0.85 SEK
0.81 SEK

Genovis business model & stock analysis

Genovis AB is a Swedish company that offers biotechnology solutions for drug research and diagnostic industries. The company was founded in Lund, Sweden in 1999 and currently employs over 30 employees. Genovis began with the development of enzymes for protein-based therapeutics, but over time expanded its business to include enzymes for improved analysis methods in mass spectrometry. Genovis has become a leading provider of innovative enzyme solutions and proteomics tools for biomedical research. The company's business model is based on providing specially developed enzymes and proteomics tools to companies in drug research and diagnostic industries. Genovis has two main business areas: marketing enzymes and providing peptide synthesis services. The first business area is the marketing of enzymes for the separation of glycosylated proteins in mass spectrometry. The company develops and produces these enzymes for various applications such as Alzheimer's research, cancer research, and infectious diseases. Genovis is also an important provider of enzymes for the investigation of antibody-drug conjugates used in novel therapeutic approaches. The second business area is providing peptide synthesis services. The company also has a diversified biotechnology infrastructure and offers analysis and synthesis services for peptides in various fields, such as immunotherapy and diagnostics. Genovis' product portfolio includes a variety of enzymes that have broad application in drug research and diagnostic industries. This includes enzymes for antibody proteolysis, enzymes for the synthesis of glycoconjugates, and enzymes for conjugated protein analysis. In addition, the company also offers specialized kits for protein analysis. Genovis kits always include all necessary components such as proteases, buffer systems, and instructions to conduct the offered experiments. In conclusion, Genovis is a leading company in the biotechnology industry that offers innovative enzyme solutions and proteomics tools for a variety of applications in medical research and diagnostics. With its diversified biotechnology infrastructure and dedicated employees, the company can meet the growing needs of its customers in the science and industry sectors and has become a key partner in the healthcare industry.

Genovis SWOT Analysis

Strengths

  • Genovis AB is a leading provider of enzyme products and technologies for the biopharmaceutical and medical device industries.
  • The company has a strong portfolio of innovative products that are well-regarded in the market.
  • Genovis AB has a highly skilled and knowledgeable team of researchers and scientists.
  • The company has established partnerships with key players in the industry, which provides access to new markets and distribution channels.

Weaknesses

  • Genovis AB may face challenges in the areas of production capacity and scalability.
  • The company may rely heavily on a limited number of customers or revenue sources, which could be a vulnerability.
  • Genovis AB's research and development costs could be high, as the company focuses on innovation and staying ahead of competitors.
  • The company may have limited brand recognition compared to larger competitors.

Opportunities

  • The biopharmaceutical industry is experiencing significant growth, providing opportunities for Genovis AB to capture a larger market share.
  • Genovis AB can leverage its expertise and technology to develop new products and expand its product offerings.
  • The increasing demand for personalized medicine and targeted therapies presents a potential market for the company.
  • Strategic collaborations and partnerships can help Genovis AB access new markets and gain a competitive edge.

Threats

  • Genovis AB operates in a highly competitive industry, facing competition from both established companies and emerging players.
  • Changes in regulations or standards could impact the company's product development and commercialization efforts.
  • Economic fluctuations may affect the purchasing power of customers and impact Genovis AB's sales.
  • The company may face intellectual property challenges, such as patent infringement or unauthorized use of its technologies.

Genovis Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Genovis historical P/E ratio, EBIT multiple, and P/S ratio

Genovis annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Genovis shares outstanding

The number of shares of Genovis was 66.06 M in 2025. This indicates how many shares Genovis is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
65.47 M Stocks
Jan 1, 2022
65.47 M Stocks
Jan 1, 2023
65.47 M Stocks
Jan 1, 2024
65.47 M Stocks
Jan 1, 2025
66.06 M Stocks
Jan 1, 2026 (e)
66.06 M Stocks
Jan 1, 2027 (e)
66.06 M Stocks
Jan 1, 2028 (e)
66.06 M Stocks

Genovis stock splits

In Genovis's history, there have been no stock splits.

Current Genovis forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
87.50 % (7)
Hold
12.50 % (1)
Sell
0.00 % (0)
12M Price Target
30.60
Last Price
19.80
Currency
SEK
12M Return Potential
54.55 %
LTM Return
0 %

Genovis Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/12/20220.10SEK-24.36 MSEK-2022 Q2
5/15/2018-SEK-7.10 MSEK-2018 Q1
2/28/2018-SEK-7.10 MSEK-2017 Q4

EESG©

Eulerpool ESG Scorecard© for the Genovis stock

22/100
8
Environment
26
Social
33
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees68.75
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Genovis shareholder structure

% Name
5.82105%
TIN Fonder
TIN Fonder
5.26139%
Case Kapitalförvaltning AB
Case Kapitalförvaltning AB
1.57334%
Schroder Investment Management (Europe) S.A.
Schroder Investment Management (Europe) S.A.
1.52752%
Nordea Funds Oy
Nordea Funds Oy
1.13804%
Amundi Asset Management, SAS
Amundi Asset Management, SAS
0.92719%
Lannebo Kapitalförvaltning AB
Lannebo Kapitalförvaltning AB

Genovis Beneficial Ownership Filings (SEC 13D/G)

Free Float
85.7%
Float Shares
-
Shares Outstanding
-

Genovis Executives and Management Board

11 members · avg. age 60 · 27 % women

FO

Mr. Fredrik Olsson (54)

Chief Executive Officer · since 2015

3.54 M SEK

Management

ML

Mr. Magnus Langberg (54)

Chief Financial Officer

–
RR

Ms. Rikke Rytter (58)

Vice President - Sales and Marketing

–
SB

Mr. Stephan Bjork (50)

Vice President - Production

–
HN

Ms. Helen Nyhlen (61)

Vice President - Quality Assurance

–
RL

Mr. Rolf Lood (41)

Vice President - Research and Development

–

Board of Directors

TJ

Mr. Torben Jorgensen (73)

Independent Chairman of the Board

496,000.00 SEK
MG

Mr. Magnus Gustafsson (53)

Independent Director

276,000.00 SEK
CL

Ms. Charlotta Ljungqvist (64)

Independent Director

276,000.00 SEK
ML

Mr. Mikael Loenn (76)

Director

231,000.00 SEK
SJ

Mr. Steve Jordan (72)

Independent Director

210,000.00 SEK

Genovis Supply Chain

Genovis Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#NameTrend
1
Thermo Fisher Scientific
Supplier·Customer·Life Sciences Tools & Services·US
0.90
0.65
0.82
0.92
0.84
0.88
#NameTrend
1
Selecta Biosciences
Supplier·Customer·Biotechnology·US
0.56
0.01
0.10
0.79
0.28
0.08

Frequently asked questions about Genovis

The business model of Genovis AB focuses on providing innovative enzyme-based technologies and solutions for the biopharmaceutical industry. Genovis offers a wide range of products and services that enable efficient drug development and production processes. The company specializes in developing and manufacturing enzymes that facilitate the analysis, modification, and quality control of biologics such as antibodies and recombinant proteins. With a strong emphasis on research and development, Genovis continuously strives to deliver cutting-edge solutions that support the advancement of therapeutic drugs. Through its unique enzyme technologies, Genovis aims to contribute to improved health outcomes for patients worldwide.

Genovis AB is primarily active in the biotechnology and life sciences industry.

The main competitors of Genovis AB in the market include Abcam plc, Merck KGaA, and Thermo Fisher Scientific Inc.

Genovis AB, a renowned biotechnology company, has an interesting history and background. Established in 1999 and headquartered in Lund, Sweden, Genovis specializes in innovative solutions for the development and production of enzymes and enzyme-based products. They possess a deep expertise in protein engineering and biomarker identification, offering cutting-edge tools and technologies for researchers in the fields of drug discovery, diagnostics, and therapeutic development. Genovis is committed to providing advanced solutions, such as their well-known enzyme portfolio, GlyCLICK™ antibody labeling kits, and biomarker assay development services. Continuously expanding and emphasizing collaborations with scientific partners globally, Genovis AB remains at the forefront of biotechnology advancements.

Genovis AB has achieved several significant milestones in its history. One of the most notable accomplishments was the development of innovative enzyme technologies for the biopharmaceutical industry. The company's unique products, such as SmartEnzymes™, have revolutionized the field by enabling efficient drug development and production processes. Genovis AB has also established successful collaborations with leading pharmaceutical companies, further strengthening its position in the market. With its continuous dedication to research and development, Genovis AB continues to make breakthroughs in enzymology, delivering cutting-edge solutions for the biotech sector.

Genovis AB is primarily present in multiple countries and regions. Its global presence spans across North America, Europe, Asia-Pacific, and other international markets. With a strong foothold in Sweden, Genovis AB has expanded its operations across various European countries, such as Germany, France, and the United Kingdom. Moreover, the company has also established significant market presence in the United States and Canada, highlighting its commitment to the North American region. Additionally, Genovis AB is actively engaged in serving customers in the Asia-Pacific region, including countries like China, Japan, and Australia.

Genovis AB represents values of innovation, expertise, and partnership in the field of biotechnology. The company is committed to providing cutting-edge solutions and technologies for protein research and drug development. With a strong focus on customer satisfaction, Genovis AB embraces a collaborative approach, working closely with researchers, pharmaceutical companies, and academic institutions. By offering advanced enzymes and tools for protein analysis and engineering, Genovis AB aims to facilitate breakthrough discoveries and enhance therapeutic development processes. Through continuous product improvement, knowledge sharing, and ethical practices, Genovis AB strives to make a positive impact in the scientific community and contribute to human health and well-being.

Analysts currently set an average price target of 35.70 SEK for the Genovis stock (median: 30.60 SEK), implying +80.3 % versus the latest price. The consensus is based on 8 analyst ratings.

Genovis Analyst Price Targets 2026

8 analysts currently rate the Genovis stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Genovis to generate revenue of 145.80 M SEK and earnings per share of 0.35 SEK.

Genovis Analyst Price Targets 2026

Converted at the current exchange rate, the Genovis share trades at 1.81 EUR (19.78 SEK).

The Genovis share (GENO.ST) is listed on 4 stock exchanges, including: Frankfurt (5GV.F), München (5GV.MU).

Genovis AB is a leading biotech company that develops innovative solutions in the field of biology and proteomics. The company was founded in 1999 and is headquartered in Lund, Sweden. The business model of Genovis is divided into three main divisions: Enzymes, Tools, and Services. The Enzyme division focuses on the development and production of recombinant proteases, including glycosidases, hydrolases, proteases, and peptidases. These enzymes play an important role in many applications in proteomics and the production of biotherapeutics, such as glycan synthesis, peptide sequencing, and therapeutic protein production. Genovis' Tools division offers a wide range of tools and accessories for proteomics research and analysis. The products offered include antibiotics, buffer systems, reagents, and kit systems. These tools are specifically tailored to the needs of researchers and technicians working with protein characterization and analysis of biological samples. Genovis' Services division offers various services to both academic and commercial customers, including custom protease and glycosidase purification services, custom assay development and optimization, glycoconjugation services, and labeling services. The company places great emphasis on high quality and customer satisfaction. The company operates an intensive research and development department aimed at developing new and improved products and services to meet customer needs. Thanks to a strong patent and brand strategy, the company has been able to acquire various valuable patents and sell its products worldwide. An important highlight of Genovis is also its focus on sustainability and environmental protection. The company strives to minimize the environmental impact of its products and services and relies on innovative solutions to reduce its carbon footprint. Overall, Genovis AB has a strong competitive advantage in the biotech market and has a successful history of innovation and research. By combining enzymes, tools, and services, the company offers its customers a comprehensive range of products and services. Genovis' broad product range allows researchers and scientists to find the right solutions for their specific needs.

The expected revenue of Genovis is 145.80 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Genovis is 23.40 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Genovis is currently 55.83. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Genovis stock.

The price-to-sales ratio (P/S) of Genovis is currently 8.96. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genovis stock.

The Eulerpool Quality Score for Genovis is 6/10.

The ISIN of Genovis is SE0002485979. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Genovis is A0Q4ER. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Genovis is GENO.ST. The ticker symbol is used to trade Genovis shares on the stock exchange.

Genovis paid dividends every year for the past 0 years.

Genovis is assigned to the 'Health' sector.

The dividends of Genovis are distributed in SEK.

All fundamentals and in-depth analysis of Genovis

Our stock analysis for Genovis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genovis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Genovis Stock
Genovis Revenue→
Genovis Stock
Genovis Net Income→
Genovis Stock
Genovis P/E→
Genovis Stock
Genovis P/S→
Genovis Stock
Genovis EBIT→
Genovis Stock
Genovis Dividend→
Genovis Stock
Genovis Directors Dealings→
Genovis Stock
Genovis Stocks→
Genovis Stock
Genovis Market capitalization→
Genovis Stock
Genovis Debt→
Genovis Stock
Genovis Liabilities→
Genovis Stock
Genovis Equity→
Genovis Stock
Genovis AAQS→
Genovis Stock
Genovis Employees→
Genovis Stock
Genovis ROE→
Genovis Stock
Genovis ROA→
Genovis Stock
Genovis ROCE→
Genovis Stock
Genovis News→
Genovis Stock
Genovis Analyst Price Targets→

Health Stocks

GenowayGenovate Biotechnology CoGenprexGenovaGensight BiologicsGenoray CoGentian Diagnostics AGenomma Lab Internacional SAB de CVGenusGenomictreeGeoVax LabsGenomics Bioscience & Technology CoAll Stocks A–Z →